Xinhua pharmaceutical Medium-A-share H-shares rose

Every reporter Tri Dan yesterday, Xinhua Pharmaceutical announced the performance forecast, the first half of the company's net profit is expected to increase 50%~100% year-on-year.　　Stimulated by this news, Xinhua pharmaceutical A-Shares, H-shares were sought after by the capital, A shares opened yesterday, less than 11 points will be sealed to trading board; Performance 50%~100% Xinhua Pharmaceutical Bulletin shows that the company expects the first half of 2009 net profit is expected to reach 39 million yuan, an increase of 50%~100%, is expected to yield 0.085 yuan per share.　　The company said that the reason for the substantial increase in performance is the strengthening of management, procurement costs over the same period of a substantial decline, and actively explore the market and the company's leading product sales scale expansion. "Yesterday Xinhua Pharmaceutical's A-share, H-shares are the main reason for the rally is the performance of the increase, of course, there are some other positive factors." The company itself is Asia's largest antipyretic and analgesic drug production and export enterprises, coupled with the recent German Bayer cooperation with the strength of production, bulk pain two products, has been achieved commercial production. And the state of a class of new drugs three double acetamiprid to achieve overseas registration, ibuprofen raw material drugs at the end of the trial production and so on.　　"These will be the new growth points for the company," analysts say. Zhongyuan Securities and pharmaceutical industry researcher Cho told the Daily Economic news reporter, "the company's low share price is also favored by funds one of the reasons." However, compared with the Xinhua pharmaceutical A shares, I think the potential of H-shares is even greater. With the current earnings per share, the H-shares are only 10 times more expensive. "The second half of the pharmaceutical unit will be stronger than the big city" Xinhua pharmaceutical substantial advance mainly depends on the main business growth. Looking at the current environment, it is not easy to find a large and growing medical unit.　　"Cho said. He argues that the drug sector has seen little gains this year, and that the pharmaceutical stocks should be better than others. Therefore, the early increase in the performance of the larger Chinese medicine unit is vulnerable to a certain degree of funding concerns. "However, the premise is that the base of net profit last year should not be too small."　　Cho at the same time. According to wind statistics, as of yesterday's release of the results of the medical unit has 32, the advance reached 14.　　Among them, people's livelihood investment is expected in the first half of 2009, net profit of about 63 million yuan; Beijing New drug industry performance also appeared to increase substantially, net profit in 1 million ~300 million yuan, the Chinese state pharmaceutical advance 60%-90%, diving medical advance 50%~80%. Recently many research institutions have also begun to express their optimism about the pharmaceutical industry. January 2009 ~ February, the pharmaceutical industry achieved a profit growth rate of 19.85%, far higher than other domestic industries, as a ray of sunshine in the economic crisis.　　Zhongyuan Securities is expected to maintain a growth rate of around 20% in the pharmaceutical industry this year and next. Zhongyuan Securities believes that the pharmaceutical industry in the second half of the trend will be stronger than the city, which benefited from the reform of the sub-industry and industry leaders in particular, deserving investors attention. They advise investors to focusFocus on bio-pharmaceuticals, proprietary Chinese medicine, medical equipment, pharmaceutical business, such as four companies.